We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Withdraws Ukoniq Approval; TG Therapeutics Initiates Voluntary Market Withdrawal
FDA Withdraws Ukoniq Approval; TG Therapeutics Initiates Voluntary Market Withdrawal
The FDA has withdrawn its approval of TG Therapeutics’ flagship lymphoma drug, Ukoniq (umbralisib), citing the possibility of increased risk of death in those taking the drug — and the company has voluntarily withdrawn the drug from market.